Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803/AMC 071 trial

Blood

Volumn 128, Issue 8, 2016, Pages 1050-1058

  Alvarnas, Joseph C ^a   Le Rademacher, Jennifer ^b   Wang, Yanli ^c   Little, Richard F ^d   Akpek, Gorgun ^e   Ayala, Ernesto ^f   Devine, Steven ^g   Baiocchi, Robert ^g   Lozanski, Gerard ^g   Kaplan, Lawrence ^h   Noy, Ariela ⁱ   Popat, Uday ^j   Hsu, Jack ^k   Morris, Lawrence E ^l   Thompson, Jason ^c   Horowitz, Mary M ^b   Mendizabal, Adam ^c   Levine, Alexandra ^a   Krishnan, Amrita ^a   Forman, Stephen J ^a   Navarro, Willis H ^m   Ambinder, Richard ⁿ   more..

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c EMMES CORPORATION   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k UNIVERSITY OF FLORIDA   (United States)

^l NORTHSIDE HOSPITAL   (United States)

^m NATIONAL MARROW DONOR PROGRAM   (United States)

ⁿ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Autologous hematopoietic cell transplantation is safe and effective in patients with HIV related lymphoma who meet standard transplant criteria.; Patients with HIV related lymphomas should not be precluded from participating in AHCT clinical trials

Indexed keywords

CARMUSTINE; CD4 ANTIGEN; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADULT; ADVERSE OUTCOME; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIV RELATED LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LARGE CELL LYMPHOMA; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; VIRUS LOAD; ADVERSE EFFECTS; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DATA BASE; DEMOGRAPHY; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LYMPHOMA, AIDS-RELATED; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; DATABASES AS TOPIC; DEMOGRAPHY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84984815928     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-664706     Document Type: Article

References (42)

1. Schulz TF, Boshoff CH, Weiss RA. HIV infection and neoplasia. Lancet. 1996; 348(9027):587-591.
2. Clifford GM, Polesel J, Rickenbach M, et al. Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005; 97(6):425-432.
3. Cooksley CD, Hwang LY, Waller DK, Ford CE. HIV-related malignancies: community-based study using linkage of cancer registry and HIV registry data. Int J STD AIDS. 1999; 10(12): 795-802.
4. Yanik EL, Napravnik S, Cole SR, et al. Incidence and timing of cancer in HIV-infected individuals following initiation of combination antiretroviral therapy. Clin Infect Dis. 2013; 57(5):756-764.
5. Kaplan LD, Straus DJ, Testa MA, et al. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med. 1997; 336(23):1641-1648.
6. Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst. 2013; 105(16):1221-1229.
7. Dunleavy K, Wilson WH. Implications of the shifting pathobiology of AIDS-related lymphoma. J Natl Cancer Inst. 2013; 105(16):1170-1171.
8. amfAR. Thirty years of HIV/AIDS: snapshots of an epidemic Web site. http://www.amfar.org/thirty-years-of-hiv/aids-snapshots-of-an-epidemic/2014. Accessed April 20 2014.
9. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996; 272(5265):1167-1170.
10. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS. Hamilton JD; VA Cooperative Study Group on AIDS. Changes in plasma HIV RNA levels and CD41 lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med. 1997; 126(12):939-945.
11. Fauci AS The AIDS epidemic-considerations for the 21st century. N Engl J Med. 1999; 341(14): 1046-1050.
12. Palella FJ Jr, Delaney KM, Moorman AC, et al. HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998; 338(13):853-860.
13. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308(4): 387-402.
14. Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2013; 2013:382-388.
15. Kaplan LD HIV-associated lymphoma. Best Pract Res Clin Haematol. 2012; 25(1):101-117.
16. Martis N, Mounier N. Hodgkin lymphoma in patients with HIV infection: a review. Curr Hematol Malig Rep. 2012; 7(3):228-234.
17. Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood. 2012; 119(14): 3245-3255.
18. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003; 101(12):4653-4659.
19. Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010; 115(15): 3017-3024.
20. Xicoy B, Miralles P, Morgades M, Rubio R, Valencia ME, Ribera JM. Long-term follow up of patients with human immunodeficiency virus infection and advanced stage Hodgkin's lymphoma treated with doxorubicin, bleomycin, vinblastine and dacarbazine. Haematologica. 2013; 98(8):e85-e86.
21. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood. 2002; 100(6):1984-1988.
22. Hartmann P, Rehwald U, Salzberger B, et al. BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection. Ann Oncol. 2003; 14(10):1562-1569.
23. Uldrick TS, Little RF. How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus. Blood. 2015; 125(8): 1226-1235, quiz 1355.
24. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23): 1540-1545.
25. Nademanee A, O'Donnell MR, Snyder DS, et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors. Blood. 1995; 85(5):1381-1390.
26. Gabarre J, Azar N, Autran B, Katlama C, Leblond V. High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet. 2000; 355(9209):1071-1072.
27. Molina A, Krishnan AY, Nademanee A, et al. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer. 2000; 89(3):680-689.
28. Krishnan A, Molina A, Zaia J, et al. Autologous stem cell transplantation for HIV-associated lymphoma. Blood. 2001; 98(13):3857-3859.
29. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood. 2005; 105(2):874-878.
30. Krishnan A, Palmer JM, Zaia JA, Tsai NC, Alvarnas J, Forman SJ. HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant. 2010; 16(9):1302-1308.
31. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy [published correction appears in J Clin Oncol. 2004; 22(2):386]. J Clin Oncol. 2003; 21(23):4423-4427.
32. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica. 2004; 89(9): 1100-1108.
33. Serrano D, Carrión R, Balsalobre P, et al. Spanish Cooperative Groups GELTAMO and GESIDA. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol. 2005; 33(4):487-494.
34. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579-586.
35. Klein J, Moeschberger ML. Survival Analysis: Statistical Methods for Censored and Truncated Data. 2nd ed. New York, NY: Springer-Verlag New York, Inc.; 2003
36. Lee EW, Wei LJ, Amato DA. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, eds. Survival Analysis: State of the Art Norwell. MA: Kluwer Academic Publishers; 1992: 237-247.
37. Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013; 369(20): 1915-1925.
38. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. Biol Blood Marrow Transplant. 2008; 14(1):59-66.
39. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood. 2009; 114(7):1306-1313.
40. Balsalobre P, Díez-Martín JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol. 2009; 27(13):2192-2198.
41. Díez-Martín JL, Balsalobre P, Re A, et al; European Group for Blood and Marrow Transplantation Lymphoma Working Party. Comparable survival between HIV1 and HIV-non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood. 2009; 113(23): 6011-6014.
42. Torres HA, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect. 2014; 20(10):O672-O679.